Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
The Smartest Dividend Stocks to Buy With $1,000 Right Now
12:47pm, Saturday, 13'th Dec 2025
Chevron is an integrated energy company with an impressive yield and an impressive dividend history. Bristol Myers has a high yield, but the drugmaker is out of favor.
Buy And Hold Portfolio For Next 10 Years: Potential $5,500 Monthly Income
08:00am, Saturday, 13'th Dec 2025
This article presents a diversified, fund-based portfolio targeting market-matching growth and a 6%+ income yield, with lower tech exposure than the S&P 500. The model portfolio, comprising 5 ETFs and
Bristol Myers Squibb Company $BMY Shares Purchased by AQR Capital Management LLC
04:48am, Saturday, 13'th Dec 2025
AQR Capital Management LLC lifted its stake in Bristol Myers Squibb Company (NYSE: BMY) by 1.7% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
06:46pm, Friday, 12'th Dec 2025
Bristol Myers Squibb (BMY) closed the most recent trading day at $52.41, moving +2.36% from the previous trading session.
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
11:36am, Friday, 12'th Dec 2025
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Pre-Market Stock Futures: The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything. The Federal Reserve, as expected, cut rates again a
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
06:32pm, Thursday, 11'th Dec 2025
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma.
Bristol Myers Squibb Announces Dividend Increase
04:16pm, Wednesday, 10'th Dec 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase.
5 Blue Chip Stocks to Buy Now That Pay Reliable 4%+ Dividends
10:14am, Wednesday, 10'th Dec 2025
Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential.
2 Pharmaceutical Stocks to Buy at a Discount
10:00am, Wednesday, 10'th Dec 2025
Weight loss drugs are the big story in the pharmaceutical industry today, but other opportunities exist, too. Bristol Myers Squibb isn't focused on weight loss, has an attractive yield, and continues
Bank of Nova Scotia Buys 183,478 Shares of Bristol Myers Squibb Company $BMY
04:28am, Wednesday, 10'th Dec 2025
Bank of Nova Scotia lifted its stake in Bristol Myers Squibb Company (NYSE: BMY) by 52.6% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor
Arrow Capital Pty Ltd Invests $2.72 Million in Bristol Myers Squibb Company $BMY
03:27am, Wednesday, 10'th Dec 2025
Arrow Capital Pty Ltd purchased a new stake in Bristol Myers Squibb Company (NYSE: BMY) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange C
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options
12:38pm, Tuesday, 09'th Dec 2025
BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative breast cancer.
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus
